Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections.
Price History & Performance
|Historical stock prices|
|Current Share Price||AU$0.31|
|52 Week High||AU$0.27|
|52 Week Low||AU$0.67|
|1 Month Change||-11.43%|
|3 Month Change||-8.82%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-40.95%|
Recent News & Updates
|ILA||AU Pharmaceuticals||AU Market|
Return vs Industry: Insufficient data to determine how ILA performed against the Australian Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how ILA performed against the Australian Market.
Stable Share Price: ILA is not significantly more volatile than the rest of Australian stocks over the past 3 months, typically moving +/- 9% a week.
Volatility Over Time: ILA's weekly volatility (9%) has been stable over the past year.
About the Company
Island Pharmaceuticals Limited, a drug research and repurposing company, focuses on the development of preventative or therapeutic drugs for viral infections. Its lead product candidate is ISLA-101, a drug for the prevention and treatment of dengue fever and other mosquito borne diseases. Island Pharmaceuticals Limited has a research collaboration agreement with Monash University to screen known molecules against host targets; research and development collaboration with Griffith University to screen for active anti-viral molecules in a rational repurposing strategy; research collaboration agreement with Compounds Australia, a drug library containing approximately four and a half thousand molecules that could be searched for drug re-purposing and pipeline development; cooperative research and development agreement with the U.S.
Island Pharmaceuticals Fundamentals Summary
|ILA fundamental statistics|
Is ILA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ILA income statement (TTM)|
|Cost of Revenue||AU$0|
Last Reported Earnings
Next Earnings Date
|Earnings per share (EPS)||0|
|Net Profit Margin||0.00%|
How did ILA perform over the long term?See historical performance and comparison
Is Island Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
In this section, we usually try to help investors determine whether Island Pharmaceuticals is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Island Pharmaceuticals has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis.
How is Island Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Island Pharmaceuticals has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
How has Island Pharmaceuticals performed over the past 5 years?
Historical Pharmaceuticals & Biotech annual earnings growth
In this section we usually display a company’s past earnings and revenues to help investors visualise the trend through time. We also gauge the company’s performance by benchmarking its returns and growth to its industry peers and the wider market. However, Island Pharmaceuticals has not provided sufficient past data to assess its track record.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have historical data.
How is Island Pharmaceuticals's financial position?
In this section we usually analyse Island Pharmaceuticals's finance health to determine how well-positioned it is against times of financial distress, in particular, its ability to manage its cash and debt levels. Island Pharmaceuticals has not provided adequate balance sheet data, its financial health cannot be properly assessed as it.
This is quite a rare situation as 97% of companies covered by Simply Wall St do have financial information.
What is Island Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ILA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ILA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ILA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ILA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ILA's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Dr. David Charles Foster is Managing Director, Chief Executive Officer and President of Island Pharmaceuticals Limited and serves as its Director since October 1, 2020. Dr Foster serves as a Director at Is...
Experienced Board: ILA's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ILA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: ILA only recently listed within the past 12 months.
Island Pharmaceuticals Limited's employee growth, exchange listings and data sources
- Name: Island Pharmaceuticals Limited
- Ticker: ILA
- Exchange: ASX
- Founded: 2017
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: AU$25.100m
- Shares outstanding: 80.97m
- Website: https://www.islandpharmaceuticals.com
- Island Pharmaceuticals Limited
- 697 Burke Road
- Suite 201
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/10/16 07:03|
|End of Day Share Price||2021/10/15 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.